Diabetes and cardiovascular franchise
Sanofi (SNY) has reorganized its diabetes and cardiovascular franchise, making it one of the largest revenue contributors to Sanofi’s pharmaceutical business. However, the franchise revenues rose ~3.9% sequentially, at constant exchange rates, to ~2.1 billion euros (about $2.23 billion) during 4Q16.
The diabetes franchise rose 1.9% sequentially to ~1.9 billion euros, mainly driven by Toujeo across all markets. Other drugs in this franchise include Amaryl, Apidra, Insuman, Lyxumia, and blood glucose monitoring products.
Lantus, a long-acting human insulin used to treat type one and type two diabetes, is sold in over 120 countries and is the largest revenue contributor for this franchise. For 4Q16, Lantus sales fell 5.1% to 1.5 billion euros, which represents nearly 75% of the company’s total diabetes sales.
Toujeo, a next generation basal insulin, was launched in the US markets in March 2015, while it received EU approvals in April 2015 and was subsequently launched in Germany, Netherlands, and some Nordic countries. It is also approved in Japan, Canada, and Australia markets.
Sanofi has also launched its insulin Glargine biosimilar, a biosimilar of Lantus, in Europe and Japan. Lantus competes with drugs like Novo Nordisk’s (NVO) Levemir and AstraZeneca’s (AZN) Byetta. Eli Lilly (LLY) and Boehringer Ingelheim have jointly developed Abasaglar, a biosimilar of Lantus, which is already approved in Europe.
The cardiovascular franchise includes Praluent and Multaq. Praluent, an injection for lowering LDL cholesterol, reported sales of 37 million euros in 4Q16.
Multaq, a drug for regularizing heart beats as a treatment for atrial fibrillation, reported a growth of 10.6% in revenues, reaching 94 million euros in 4Q16.
Notably, to divest risk, investors can consider ETFs like VanEck Vectors Pharmaceutical ETF (PPH), which has 4.9% of its total assets in Sanofi.